The HSCI reserves the right to not award any pilot grants as a result of this call for proposals.Īll researchers with “Principal Investigator” status who are located within either Harvard University or one of its hospital affiliates are welcome to apply. The HSCI diabetes Program intends to award up to two grants as a result of this call for proposals.Īny pilot grants awarded during this cycle will be funded at up to $100,000 in total annual costs (including indirect costs, maximum 20% of total direct costs) for each participating lab, for a period of up to two years.Īll proposals will be reviewed by members of the HSCI Diabetes Program and/or the HSCI Executive Committee. Collaborative proposals are welcome, particulary where one of the labs has expertise in diabetes research. Approaches of interest include – but are not limited to – novel immune interventions to regulate or eliminate autoreactive T lymphocytes, interventions to modify local antigen presentation, and genetic manipulations of stem cell-derived islet cells to protect them against allo- and autoimmunity. A particular focus of the Diabetes Program lies in developing solutions that will enable the transplantation of stem cell-derived islet cells into patients with autoimmune diabetes. The purpose of this call for applications is to fund innovative projects rooted in our understanding of tumor-immune interactions to avert the immune attack on pancreatic islet cells that underlies type 1 diabetes. The Harvard Stem Cell Institute (HSCI) Diabetes Program invites applications for pilot grant funding.
Up to $100,000 per year per lab for up to two years 'Learning from cancer immunology to cure autoimmune diabetes'
0 kommentar(er)
